CL2023001361A1 - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas - Google Patents
Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetasInfo
- Publication number
- CL2023001361A1 CL2023001361A1 CL2023001361A CL2023001361A CL2023001361A1 CL 2023001361 A1 CL2023001361 A1 CL 2023001361A1 CL 2023001361 A CL2023001361 A CL 2023001361A CL 2023001361 A CL2023001361 A CL 2023001361A CL 2023001361 A1 CL2023001361 A1 CL 2023001361A1
- Authority
- CL
- Chile
- Prior art keywords
- cyclopentathiophen
- activating factor
- platelet activating
- receptor antagonists
- factor receptor
- Prior art date
Links
- ADEGUPDGFKUYII-UHFFFAOYSA-N 2H-cyclopenta[b]thiophene-2-carboxamide Chemical class S1C=2C(=CC1C(=O)N)C=CC=2 ADEGUPDGFKUYII-UHFFFAOYSA-N 0.000 title abstract 2
- 108700023400 Platelet-activating factor receptors Proteins 0.000 title 1
- 102000030769 platelet activating factor receptor Human genes 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 abstract 1
- 108010003541 Platelet Activating Factor Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Ciclopentatiofen carboxamidas de la Fórmula (I.0), en donde R1, R2, R3, R4 y n son como se definen en la descripción y las reivindicaciones, y las sales de este aceptables desde el punto de vista farmacéutico pueden usarse en métodos para el tratamiento de enfermedades que pueden estar influenciadas por antagonizar la actividad mediada por el receptor del factor de activación de plaquetas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207719 | 2020-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001361A1 true CL2023001361A1 (es) | 2023-11-03 |
Family
ID=73543025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001361A CL2023001361A1 (es) | 2020-11-16 | 2023-05-11 | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11766443B2 (es) |
| EP (1) | EP4244229A1 (es) |
| JP (1) | JP7465368B2 (es) |
| KR (1) | KR20230109692A (es) |
| CN (2) | CN116745300A (es) |
| AR (1) | AR124070A1 (es) |
| AU (1) | AU2021379248A1 (es) |
| CA (1) | CA3200710A1 (es) |
| CL (1) | CL2023001361A1 (es) |
| CO (1) | CO2023005894A2 (es) |
| CR (1) | CR20230211A (es) |
| DO (1) | DOP2023000090A (es) |
| EC (1) | ECSP23036210A (es) |
| IL (1) | IL302769A (es) |
| MX (1) | MX2023005678A (es) |
| TW (1) | TW202237620A (es) |
| WO (1) | WO2022101377A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3502392A1 (de) | 1985-01-25 | 1986-07-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| PH30676A (en) * | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| DE3909012A1 (de) | 1989-03-18 | 1990-09-20 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| DE4132763A1 (de) | 1991-10-02 | 1993-04-08 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US20050032713A1 (en) * | 2002-03-27 | 2005-02-10 | Wurtman Richard J. | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| CA2670026A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterotricyclic metalloprotease inhibitors |
-
2021
- 2021-11-12 CN CN202180076849.5A patent/CN116745300A/zh active Pending
- 2021-11-12 AU AU2021379248A patent/AU2021379248A1/en active Pending
- 2021-11-12 CR CR20230211A patent/CR20230211A/es unknown
- 2021-11-12 EP EP21806745.2A patent/EP4244229A1/en active Pending
- 2021-11-12 IL IL302769A patent/IL302769A/en unknown
- 2021-11-12 MX MX2023005678A patent/MX2023005678A/es unknown
- 2021-11-12 KR KR1020237020295A patent/KR20230109692A/ko unknown
- 2021-11-12 CN CN202311341729.0A patent/CN117624188A/zh active Pending
- 2021-11-12 CA CA3200710A patent/CA3200710A1/en active Pending
- 2021-11-12 JP JP2022562298A patent/JP7465368B2/ja active Active
- 2021-11-12 US US17/524,759 patent/US11766443B2/en active Active
- 2021-11-12 WO PCT/EP2021/081459 patent/WO2022101377A1/en active Application Filing
- 2021-11-15 AR ARP210103159A patent/AR124070A1/es unknown
- 2021-11-15 TW TW110142333A patent/TW202237620A/zh unknown
-
2023
- 2023-05-08 CO CONC2023/0005894A patent/CO2023005894A2/es unknown
- 2023-05-11 CL CL2023001361A patent/CL2023001361A1/es unknown
- 2023-05-11 DO DO2023000090A patent/DOP2023000090A/es unknown
- 2023-05-17 EC ECSENADI202336210A patent/ECSP23036210A/es unknown
- 2023-07-14 US US18/221,936 patent/US20230355638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR124070A1 (es) | 2023-02-08 |
| WO2022101377A1 (en) | 2022-05-19 |
| IL302769A (en) | 2023-07-01 |
| US20220160725A1 (en) | 2022-05-26 |
| CN116745300A (zh) | 2023-09-12 |
| US20230355638A1 (en) | 2023-11-09 |
| DOP2023000090A (es) | 2023-06-15 |
| CO2023005894A2 (es) | 2023-05-29 |
| CR20230211A (es) | 2023-07-13 |
| KR20230109692A (ko) | 2023-07-20 |
| CN117624188A (zh) | 2024-03-01 |
| ECSP23036210A (es) | 2023-06-30 |
| US11766443B2 (en) | 2023-09-26 |
| CA3200710A1 (en) | 2022-05-19 |
| MX2023005678A (es) | 2023-05-26 |
| JP7465368B2 (ja) | 2024-04-10 |
| TW202237620A (zh) | 2022-10-01 |
| AU2021379248A1 (en) | 2023-06-22 |
| EP4244229A1 (en) | 2023-09-20 |
| JP2023521200A (ja) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21012498A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| CL2021001991A1 (es) | Compuestos 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria cdk2. | |
| PA8587101A1 (es) | Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos | |
| ECSP21036982A (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso | |
| CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| PA8748101A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
| CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| CR8928A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas | |
| CR7880A (es) | Derivados sustituidos de pirrolo-pirazol como inhibidores de quinasa | |
| PE20210856A1 (es) | Derivados sustituidos de la carboxamida dihidropirazolo pirazina | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| CL2019002601A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. | |
| AR038483A1 (es) | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides | |
| DOP2022000130A (es) | Derivados de benzimidazol | |
| CL2023002731A1 (es) | Análogos, sales, composiciones y métodos de uso de la psilocibina | |
| ECSP21080966A (es) | Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 | |
| MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
| CL2023001361A1 (es) | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas | |
| DOP2023000195A (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| CO2021001925A2 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
| AR049343A1 (es) | Derivados tioeter, su obtencion y utilizacion de los mismos como agentes farmaceuticos | |
| CL2023003117A1 (es) | Compuestos agonistas de gpr35 | |
| CO2023013714A2 (es) | Análogos, sales, composiciones y métodos de uso de la psilocibina | |
| UY27534A1 (es) | Amidas de ácido antranílico y uso farmacológico de las mismas. |